Benjamin Besse, MD, Gustave Roussy Institute, Villejuif, France, describes the findings from two major non-small cell lung cancer (NSCLC) trials, the IMpower010 trial (NCT02486718) and the PEARLS/KEYNOTE-091 study (NCT02504372). Both trials investigated the use of adjuvant chemotherapy in patients with NSCLC. The IMpower010 trial observed the effects of atezolizumab, compared to best supportive care, after adjuvant chemotherapy. The KEYNOTE-091 trial investigated the effects of pembrolizumab compared to a placebo drug after standard adjuvant therapy. Results from both trials showed an overall positive effect of adjuvant therapy, specifically in disease-free progression. Prof. Besse highlights discrepancies in patient subgroups within these trials, most notably the level of PD-1 expression. He also briefly discusses key biomarkers that would help better understand which patients would benefit from adjuvant therapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

свернуть